Efficacy of ciclesonide, budesonide and beclomethasone dipropionate in moderate persistent bronchial asthma: a comparative study

Mohana Rupa L.; Maduram A.; Jagan Nadipelly

doi:10.18203/2319-2003.ijbcp20194269

Authors

Mohana Rupa L. Department of Pharmacology, Maheshwara Medical College and Hospital, Chitkul, Isnapur, Patancheru, Telangana, India
Maduram A. Department of Pharmacology, Sri Sathya Sai Medical College and Research Institute, Tiruporur, Guduvancherry, Ammapettai, Sembakkam, Tamil Nadu, India
Jagan Nadipelly Department of Pharmacology College of Medicine, Texila American University, Georgetown, Guyana, South America

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20194269

Keywords:

Ciclesonide, Budesonide, Beclomethasone, Moderate persistent asthma

Abstract

Background: The objective of the present study was to compare the efficacy and adverse effects of ciclesonide with that of budesonide and beclomethasone dipropionate in moderate persistent cases of bronchial asthma.

Methods: This was an open label, randomized parallel group study done in Government General and Chest Hospital, Hyderabad for a period of 12 weeks. Each group had 20 patients. Group A was given ciclesonide inhalational therapy 160 mcg once daily. Group B was given budesonide inhalational therapy 400 mcg twice daily. Group C was given beclomethasone dipropionate inhalational therapy 400 mcg twice daily.

Results: Symptomatic improvement was observed in all three groups. At end point, mean FEV₁in ciclesonide treatment group improved by 23.84% compared with 15.24% in budesonide and 12.93% in beclomethasone treatment groups. At end point, mean FVC value in ciclesonide treatment group improved by 6.44% compared with 1.5% in budesonide and 1.06% in beclomethasone groups. Mean FEV₁/FVC also improved by 16.56% in ciclesonide group compared with 13.68% in budesonide and 11.93% in beclomethasone groups. No adverse effects were reported in any of the treatment groups.

Conclusions: This study showed that ciclesonide is superior to budesonide and beclomethasone in improving lung function, decreasing symptoms and need for rescue medication in moderate persistent asthma.

Metrics

Metrics Loading ...

References

Masoli M, Fabian D, Holt S, Beasley R, Global initiative for asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469-78.

Global Initiative for Asthma. Global strategy for asthma management and prevention, 2009. Available at: http://www.ginasthma.com. Accessed on 20 March 2019.

National Heart Lung and Blood Institute Expert panel report 3 (EPR3): guidelines for the diagnosis and management of asthma, 2007. Available at: http://www.nhlbi.nih.gov. Accessed on 20 March 2019.

Raphael GD, Lanier RQ, Baker J, Edwards L, Richard K, Lincourt WR. A comparison of multiple doses of ciclesonide and beclomethasone dipropionate in subjects with persistent asthma. J Allergy Clin Immunol. 1999;103:796-803.

Louis R, Lau LCK, Bron AO, Rodaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9-16.

Asthma Allergy and Airway Research Center. Information for Health Care Professionals. Asthma assessment. Available at: http://www.upmc.Edu /AAARC/professionals.htm. Accessed on 20 March 2019.

Dahl R. Ciclesonide for the treatment of asthma. Ther Clin Risk Manag. 2006;2(1):25-38.

Chiu KC, Chou YL, Hsu JY, Lin MS, Lin CH, Chou PC, et al. Comparison of the efficacy of ciclesonide with that of budesonide in mild to moderate asthma patients after step-down therapy: a randomised parallel-group study. NPJ Prim Care Respir Med. 2014;24:14010.